Norges Bank Vaxcyte, Inc. Transaction History

Norges Bank

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$60.06 - $78.77 $59.1 Million - $77.5 Million	984,464 New	984,464 $74.3 Million
Q4 2023 Feb 09, 2024	BUY	$45.35 - $63.41 $41.5 Million - $58.1 Million	915,512 New	915,512 $57.5 Million
Q3 2023 Nov 13, 2024	BUY	$46.0 - $53.1 $36.1 Million - $41.7 Million	785,543 New	785,543 $40 Million
Q2 2023 Aug 14, 2024	SELL	$34.66 - $54.07 $8.09 Million - $12.6 Million	-233,430 Reduced 23.71%	751,034 $37.5 Million
Q1 2023 May 15, 2024	BUY	$36.27 - $47.2 $15.1 Million - $19.7 Million	416,636 New	416,636 $15.6 Million
Q4 2022 Feb 14, 2023	BUY	$20.58 - $47.95 $2.59 Million - $6.04 Million	125,879 New	125,879 $6.04 Million
Q1 2021 May 07, 2021	SELL	$18.66 - $29.16 $373,200 - $583,200	-20,000 Closed	0 $0
Q4 2020 Mar 02, 2021	BUY	$26.57 - $51.74 $531,400 - $1.03 Million	20,000 New	20,000 $531,000
Q4 2020 Feb 10, 2021	SELL	$26.57 - $51.74 $531,400 - $1.03 Million	-20,000 Closed	0 $0
Q3 2020 Nov 12, 2021	BUY	$26.5 - $55.4 $530,000 - $1.11 Million	20,000 New	20,000 $988,000
Q3 2020 Nov 10, 2020	SELL	$26.5 - $55.4 $530,000 - $1.11 Million	-20,000 Closed	0 $0
Q2 2020 Aug 13, 2021	BUY	$26.15 - $35.45 $523,000 - $709,000	20,000 New	20,000 $632,000

352

122M

775K

433K

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $5.25B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.